4 completed, 1 recruiting, 1 suspended, 1 unknown. 6 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 1, Suspended 1, Unknown 1 |
| Phase 2 | 3 | Recruiting 1, Suspended 1, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow CYC065: new trials by email Literature Review of CYC065 trials Research Report on CYC065
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects Fadraciclib - Healthy | Early Phase 1 | Completed | Cyclacel Pharmaceuticals, Inc. | 8 | 2023-03-03 | 2024-09-19 |
| A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) fadraciclib - Leukemia, Myelodysplastic Syndrome(MDS) | Phase 1 / Phase 2 | Suspended | Cyclacel Pharmaceuticals, Inc. | 210 | 2021-10-22 | 2024-02-08 |
| A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma Fadraciclib - Solid Tumor, Adult, Lymphoma | Phase 1 / Phase 2 | Unknown | Cyclacel Pharmaceuticals, Inc. | 330 | 2021-07-12 | 2024-01-25 |
| CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS CYC065, Venetoclax - AML, MDS | Phase 1 | Completed | Cyclacel Pharmaceuticals, Inc. | 14 | 2019-08-02 | 2024-09-19 |
| CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL CYC065, Venetoclax - Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 1 | Completed | Cyclacel Pharmaceuticals, Inc. | 5 | 2019-01-25 | 2024-01-25 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers CYC065 - Cancer | Phase 1 | Completed | Cyclacel Pharmaceuticals, Inc. | 60 | 2015-09-28 | 2024-05-31 |
Myelodysplastic Syndromes (2) · Neoplasms (2) · Recurrence (2) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1)
Cyclacel Pharmaceuticals, Inc. (6) · Gustave Roussy, Cancer Campus, Grand Paris (1)
United States (6) · Spain (2) · Denmark (1) · France (1) · Italy (1) · Netherlands (1) · South Korea (1) · United Kingdom (1)
Birgit Geoerger, MD (1) · Gautam Borthakur, MD (1) · Geoffrey Shapiro, MD (1) · Mark H Kirschbaum, MD (1) · Mark Kirschbaum, MD (1)
PMID 31538815, PMID 32645016, PMID 33892407, PMID 34347542, PMID 34543871, PMID 35292802, PMID 41838385, PMID 42686334
2016 (1)